Kiora Pharmaceuticals eliminates $4.75M in milestone payments to Sentrx; grants animal health license for royalty

KIORA PHARMACEUTICALS INC

Amendment cancels up to $4.75M in near-term milestones Kiora owed Sentrx under 2018 license.
Kiora grants Sentrx exclusive license to KIO-201 patents for veterinary use; Kiora receives low single-digit royalty on net sales.
Kiora retains optionality to source alternative manufacturing partners for KIO-201.
KIO-201 is a modified hyaluronic acid for persistent corneal epithelial defects, a rare disease.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.